BioView: Can Sanmed Rebuild Asia After the 2025 Collapse
Renewing the Sanmed agreement in March 2026 gives BioView a commercial option back in China, but 2025 already showed that a renewed contract does not by itself rebuild Asia. The real test starts only if the channel returns to repeat orders rather than headlines.
The main article already established that the U.S. is carrying BioView while Asia has shifted from a growth engine into a pressure point. This follow-up isolates the Sanmed thread because on March 8, 2026 the company renewed its distribution agreement with the Chinese partner again, right after a year in which Asia nearly disappeared from the numbers.
What still works is that this channel is not starting from zero. Sanmed still has exclusive territory, it received the relevant regulatory permit in China during 2024 in the context of its clinical trial, and by the date of the annual report BioView had sold roughly 100 systems to it. What is not working is the translation of that setup into revenue. In 2025, Asia revenue by customer location fell to NIS 1.168 million, and Sanmed disappeared from the list of customers contributing more than 10% of revenue.
That is why the March 2026 extension matters, but is not enough. The market has already seen a previous renewal in February 2024, and what followed was the 2025 collapse. So the question now is not whether Sanmed still exists on paper, but whether it can return to generating repeat orders at a scale that matters for a company with NIS 19.93 million of annual revenue.
The financial context sharpens the point. At the end of 2025 BioView had NIS 4.92 million of cash, NIS 7.553 million of working capital, and the auditor added an emphasis paragraph regarding the company's financial condition and management plans. On March 19, 2026 the company also drew NIS 1 million from a short-term credit line. In a company with this profile, an Asia recovery needs to be commercial and clean, not just narrative.
Where Asia Actually Broke
The core insight is that 2025 was not a small wobble, but a break in a channel that used to matter. In the customer-location table, Asia revenue fell from NIS 12.542 million in 2023 to NIS 5.609 million in 2024 and then to only NIS 1.168 million in 2025. Over two years, Asia dropped from 36.1% of revenue to 5.9%, and from 2024 to 2025 alone it erased NIS 4.441 million, or 77.6% of the group's entire revenue decline.
| Metric | 2023 | 2024 | 2025 | What it means |
|---|---|---|---|---|
| Asia revenue by customer location | 12,542 | 5,609 | 1,168 | The channel almost reset to zero |
| Asia share of total revenue | 36.1% | 21.9% | 5.9% | A meaningful engine became marginal |
| Sanmed as a major customer | 10,435, or 29% of revenue | 5,247, or 20% of revenue | No longer listed among customers above 10% of revenue | Concentration broke, but so did volume |
| Recognized revenue from the Sanmed software and services agreement | 3,274 | 3,159 | Full consideration had already been received by end-2024 | There was no one-off bridge left in 2025 |
This table combines two disclosure lenses that are not mechanically identical. The customer-location table is geographic, while the major-customer disclosure is concentration by customer name. But the direction is too consistent to ignore. Asia collapsed, and the distributor most associated with China stopped being a material customer.
Why the Renewal Alone Is Not Enough
What matters now is that the bottleneck has moved from contract to commercialization. Sanmed first received exclusive distribution rights in January 2019 across China, Hong Kong, Macau, and Taiwan. The agreement includes annual purchase targets, and failure to meet them gives BioView the right to cancel exclusivity and even the agreement itself. The contract was renewed for two more years in February 2024 and again for another two years on March 8, 2026. The fact that one renewal already preceded the 2025 collapse tells you something important. Contract renewal alone is not proof of demand.
That distinction becomes even clearer when looking at the software license and services agreement signed with Sanmed on March 9, 2023. Under that agreement, BioView committed to support Sanmed through the Chinese regulatory process and to provide a software license. The total consideration was about $1.75 million, paid in six milestone-based installments. Sanmed received the regulatory permit in China during 2024, and the full contractual consideration had already been collected by the end of 2024. By the time 2026 starts, both the permit and the one-off money have already run through the story.
That is the key point. If Asia returns in 2026, it will have to return through real commercial pull-through in systems, services, and upgrades, not through the same bridge of milestone-based license and service revenue that has already ended. At the same time, the optionality is not trivial. The company says it has sold roughly 100 systems to Sanmed so far. That is a real installed base. But 2025 also showed that an installed base by itself does not hold up a regional channel if fresh order flow weakens.
Between the lines, BioView itself is not presenting Sanmed as a complete answer. The annual report says the company continues to invest resources in CTC in order to find additional business partners, and that discussions are ongoing with other partners similar to Sanmed. That is an indirect admission that one renewed distributor agreement still does not solve the commercialization question.
The Reset Arrived Together With a Sales Handover
The Sanmed renewal landed in the same month that BioView changed the executive responsible for sales. On January 29, 2026 the company reported that Elad Kfir, who had served as Vice President of Marketing and Sales since July 4, 2010, would cease serving on March 18, 2026, and that the departure was not tied to circumstances requiring disclosure. On March 5, 2026 Hagai Langbeheim entered the role.
What sharpens the picture is Langbeheim's profile. The appointment filing shows that he came from inside the company, after serving as service manager for five and a half years, and that was also the only role disclosed under his principal occupations over the last five years. In other words, BioView chose to attempt this Asia reset not with an externally disclosed global commercial operator, but with an internal promotion from the service side of the business.
That is not automatically negative. If the company wants tighter linkage between the installed base, after-sale service, and upgrade revenue, there is logic in appointing someone with deep product and customer familiarity. But at this point the filings offer, at most, an organizational reset, not proof of renewed commercial acceleration. Even the timeline makes that clear. Langbeheim started on March 5, 2026, the Sanmed agreement was renewed on March 8, 2026, and Kfir formally ended his tenure on March 18, 2026. This is a transition point, not an endpoint.
What Would Count as a Real Recovery
BioView is too small for Asia to be just a colorful side topic. Merely returning to the 2024 level of Asia revenue would add NIS 4.441 million to the 2025 revenue base, or about 22.3% of last year's total revenue. That explains why the renewed Sanmed agreement matters so much. But precisely because the number is meaningful, the quality of the recovery matters almost as much as the fact of recovery.
A real recovery would look different from a headline about a renewed contract:
- Asia revenue needs to rise from the negligible 2025 level through a mix of systems, upgrades, and service, not through another one-off recognition event.
- Sanmed needs to re-emerge as a material customer, or at least produce a transaction cadence that proves repeat demand rather than a single event.
- The new sales leadership needs to show that the renewed channel is turning into orders, not only operational continuity.
- Given the company's financial profile, the recovery also has to be economically useful, meaning it should support both revenue and cash rather than only improve the story on paper.
Conclusion
The bottom line is that Sanmed is back as an option, not yet as proof. There is still exclusive territory, a regulatory step that has already been completed, a base of roughly 100 systems, and a renewed two-year agreement. All of that explains why BioView is not walking away from this channel.
But 2025 remains the fact that is hard to step around. After a prior contract renewal, after the Chinese regulatory permit had already been obtained, and after the full value of the software and services agreement had already been collected by end-2024, Asia almost disappeared and Sanmed stopped being a material customer. That makes 2026 look like a reset year for this channel, not a breakout year.
What will shape the market's reading in the next reports is fairly simple: orders, not contract language. If Asia lifts off the 2025 floor and does so without relying on another one-off bridge, the Sanmed thread can become highly material to the BioView thesis again. If not, the March 2026 renewal will remain an extension of optionality rather than a restored growth channel.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.